Truist Securities increased its price target for Medtronic plc (MDT) to $110 from $103, maintaining a Hold rating, following strong fiscal second-quarter revenue growth. The growth was primarily driven by the company's Pulsed Field Ablation (PFA) technology, which led to a 71% year-over-year organic rise in sales for the cardiac ablation solutions division. Despite a revenue beat, an operating margin miss and increased reinvestment limited upside growth and profit acceleration.

<p>Truist Securities increased its price target for Medtronic plc (MDT) to $110 from $103, maintaining a Hold rating, following strong fiscal second-quarter revenue growth. The growth was primarily driven by the company's Pulsed Field Ablation (PFA) technology, which led to a 71% year-over-year organic rise in sales for the cardiac ablation solutions division. Despite a revenue beat, an operating margin miss and increased reinvestment limited upside growth and profit acceleration.</p>

Medtronic (MDT) Price Target Raised as PFA Technology Drives Q2 Revenue Gains